Title |
Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward
|
---|---|
Published in |
International Journal of Chronic Obstructive Pulmonary Disease, January 2018
|
DOI | 10.2147/copd.s148673 |
Pubmed ID | |
Authors |
Magnus Ekström, Thomas Ringbaek |
Abstract |
Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4-8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 25 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 20% |
Student > Ph. D. Student | 5 | 20% |
Student > Bachelor | 3 | 12% |
Researcher | 3 | 12% |
Professor | 2 | 8% |
Other | 3 | 12% |
Unknown | 4 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 56% |
Nursing and Health Professions | 2 | 8% |
Business, Management and Accounting | 2 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Social Sciences | 1 | 4% |
Other | 1 | 4% |
Unknown | 4 | 16% |